Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Novavax's COVID-19/Influenza Combo Vaccine Shows Immunogenicity In Early-Study

  • Novavax Inc (NASDAQ:NVAX) has announced initial results from the Phase 1/2 trial of its COVID-Influenza Combination Vaccine (CIC), combining the COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate. 
  • The CIC trial demonstrated that the combination vaccine is feasible, well-tolerated, and immunogenic.
  • The safety and tolerability profile of the combination vaccine was consistent with the stand-alone NVX-CoV2373 and quadrivalent nanoparticle influenza vaccine reference formulations in the trial. 
  • Also See: Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report.
  • The combination vaccine was found to be generally well-tolerated. Serious adverse were rare, and none were assessed as related to the vaccine.
  • The preliminary trial results found that various CIC vaccine formulations induced immune responses in participants comparable to reference stand-alone influenza and stand-alone COVID-19 vaccine formulations.
  • Modeling results also showed that a combined formulation has the potential to reduce total antigen amount by up to 50% overall, optimizing production and delivery.
  • The Company plans to start a Phase 2 confirmation trial by the end of 2022.
  • Price Action: NVAX shares are down 0.92% at $54.09 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.